<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335725">
  <stage>Registered</stage>
  <submitdate>16/07/2010</submitdate>
  <approvaldate>20/07/2010</approvaldate>
  <actrnumber>ACTRN12610000584033</actrnumber>
  <trial_identification>
    <studytitle>Cardiotoxicity assessment by gated-single photon computed tomography (SPECT) in patients with previous breast cancer undergoing chemo- and/or radiotherapy</studytitle>
    <scientifictitle>Cardiotoxicity assessment by gated-SPECT in patients with previous breast cancer undergoing chemo- and/or radiotherapy for comparison of coronary reserve</scientifictitle>
    <utrn>U1111-1116-0977</utrn>
    <trialacronym>CFRBC</trialacronym>
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>cardiotoxicity in breast cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Anthracyclines: one cycle once every 21 days for 4-6 cycles; bolus as per imput infusion (comprehensive procedure duration half an hour), 90 mg/m2:  radiotherapy on chest 5 day per week for 6 weeks; overall 60 Gy. overall observation over 48 months</interventions>
    <comparator>Coronary flow reserve (CFR) control pre and post-therapy;
All patients undergone single-day stressrest 99mTc-tetrofosmin Myocardial Perfusion Imaging (MPI) by gated SPECT according to the European Association of Nuclear Medicine and European Society of Cardiology recommendations [Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, et al. European Association of Nuclear Medicine (EANM)/European Society of Cardiology (ESC) procedural guidelines for myocardial perfusion imaging in nuclear cardiology. Eur J Nucl Med Mol Imaging 2005;32:85597.]. A pharmacological dipyridamole-induced stress according to a standardized protocol is carried out monitoring heart rate and rhythm, blood pressure and electrocardiography (EKG). 
At peak stress 370 MBq of 99mTc-tetrofosmin are injected intravenously. Two to three hours after the stress test, 1,110 MBq of 99mTc-tetrofosmin are injected at rest. Gated-SPECT imaging (16 frames per cardiac cycle) is executed 30 and 60 min after the tracer injection for the post-stress and rest study, respectively, using a dual head gamma camera. CFR calculation is carried out according to a validated method (Storto G et al. Estimation of coronary flow reserve by Tc-99m sestamibi imaging in patients with coronary artery disease: comparison with the results of intracoronary Doppler technique. J Nucl Cardiol. 2004 Nov-Dec;11(6):682-8.</comparator>
    <control>Active</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>CFR assessment by gated-SPECT</outcome>
      <timepoint>ad interim 6 months evaluation; final assessment at 48 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>CFR assessment by gated-SPECT</outcome>
      <timepoint>ad interim 6 months evaluation; final assessment at 48 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>patients with previous breast cancer undergoing chemo- and or radiotherapy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>know coronary artery disease, cardiac heart failure (CHF), hypertrophic myocardiopathy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Both</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>5/07/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Italy</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS);  Centro di Riferimento Oncologico di Basilicata (CROB)</primarysponsorname>
    <primarysponsoraddress>via P. Pio 1; 85028 Rionero in Vulture (Pz)</primarysponsoraddress>
    <primarysponsorcountry>Italy</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS);  Centro di Riferimento Oncologico di Basilicata (CROB)</fundingname>
      <fundingaddress>via P. Pio 1; 85028 Rionero in Vulture (Pz)</fundingaddress>
      <fundingcountry>Italy</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>Federico II</othercollaboratorname>
      <othercollaboratoraddress>via Pansini 5 , 80131 Naples</othercollaboratoraddress>
      <othercollaboratorcountry>Italy</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Assessment of coronary flow reserve by non-invasive methodology (myocardial  perfusion scintigraphy and cardiac function evaluation) in patients undergoing chemo- and or radio-therapy following breast cancer surgery.
Such non invasive procedure could be useful in detecting early microvascular coronary bed damages due to adiuvant interventions</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>IRCCS CROB</ethicname>
      <ethicaddress>via P. Pio n 1; 85028 Rionero in Vulture (Pz)</ethicaddress>
      <ethicapprovaldate>5/06/2007</ethicapprovaldate>
      <hrec>377</hrec>
      <ethicsubmitdate />
      <ethiccountry>Italy</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mr. Giovanni Storto MD FEBNM</name>
      <address>via P. Pio 1, 85028 Rionero in Vulture (Pz)</address>
      <phone>+39-0972-726560</phone>
      <fax />
      <email>giosto24@hotmail.com</email>
      <country>Italy</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mr. Giovanni Storto MD FEBNM</name>
      <address>via P. Pio 1, 85028 Rionero in Vulture (pz)</address>
      <phone>+39-0972-726560</phone>
      <fax />
      <email>giosto24@hotmail.com</email>
      <country>Italy</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mr. Giovanni Storto MD FEBNM</name>
      <address>via P. Pio 1, 85028 Rionero in Vulture (pz)</address>
      <phone>+39-0972-726560</phone>
      <fax />
      <email>giosto24@hotmail.com</email>
      <country>Italy</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>